Implications of Birth-Dose Vaccination against Hepatitis B Virus in Southeast Asia

The World Health Organization (WHO) South-East Asia Regional Office (SEARO) covers 11 countries with a combined population of about 2 billion people, making it the most populous of the six WHO regions. In 1992, the WHO advocated including the hepatitis B vaccine in the Expanded Program of Immunization (EPI) and vaccinating all infants and children three times within 1 year of birth (HepB3). Recently, the WHO advocate birth-dose hepatitis B vaccination (HepB-BD) as soon as possible after birth, preferably within 24 hours. In 2016, the SEARO endorsed a regional hepatitis B control goal with a target of hepatitis B surface antigen (HBsAg) seroprevalence of ≤1% among children aged ≥5 years by 2020. Of the 11 SEARO countries, four achieved this target on schedule. Out of these four countries, two countries (Bangladesh and Nepal) have not adopted HepB-BD in EPI program. On the other hand, the coverage of HepB3 is not satisfactory in some SEARO countries, including India which adopted HepB-BD but could not achieve the overall target of SEARO. Thus, it is a point of debate whether emphasis should be placed on proper implementation of HepB3 or whether a new agenda of HepB-BD should be incorporated in developing countries of SEARO. The article discusses strengthening and expanding the Hepatitis B vaccination program in SEARO countries with an emphasis on HepB and HepB-BD programs.

[1]  G. Gartlehner,et al.  [Prevention of Mother-To-Child Transmission of Hepatitis B Virus: Guidelines on Antiviral Prophylaxis in Pregnancy]. , 2022, Gesundheitswesen (Bundesverband der Arzte des Offentlichen Gesundheitsdienstes (Germany)).

[2]  P. Ashok Kumar,et al.  Hepatitis-B virus infection in India: Findings from a nationally representative serosurvey, 2017-18. , 2020, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[3]  S. Chunsuttiwat,et al.  Progress Toward Hepatitis B Control — South-East Asia Region, 2016–2019 , 2020, MMWR. Morbidity and mortality weekly report.

[4]  Yared Tadesse,et al.  Introduction of birth dose of hepatitis B virus vaccine to the immunization program in Ethiopia: an economic evaluation , 2020, Cost Effectiveness and Resource Allocation.

[5]  M. Hellard,et al.  Use of controlled temperature chain and compact prefilled auto-disable devices to reach 2030 hepatitis B birth dose vaccination targets in LMICs: a modelling and cost-optimisation study. , 2020, The Lancet. Global health.

[6]  M. Kumar,et al.  Liver diseases in the Asia-Pacific region: a Lancet Gastroenterology & Hepatology Commission , 2019, The Lancet Gastroenterology & Hepatology.

[7]  P. Parija,et al.  Hepatitis B vaccine birth dose in India: time to reconsider , 2020, Human vaccines & immunotherapeutics.

[8]  K. Ueda,et al.  A meta-analysis on genetic variability of RT/HBsAg overlapping region of hepatitis B virus (HBV) isolates of Bangladesh , 2019, Infectious Agents and Cancer.

[9]  H. Janssen,et al.  Limited sustained response after stopping nucleos(t)ide analogues in patients with chronic hepatitis B: results from a randomised controlled trial (Toronto STOP study) , 2019, Gut.

[10]  Zhengming Chen,et al.  Chronic hepatitis B virus infection and total and cause-specific mortality: a prospective cohort study of 0.5 million people , 2019, BMJ Open.

[11]  C. Staton,et al.  Cost-effectiveness of birth-dose hepatitis B vaccination among refugee populations in the African region: a series of case studies , 2019, Conflict and Health.

[12]  Y. Hiasa,et al.  Treatment of chronic hepatitis B naïve patients with a therapeutic vaccine containing HBs and HBc antigens (a randomized, open and treatment controlled phase III clinical trial) , 2018, PloS one.

[13]  Minal K. Patel,et al.  Implementing a Birth Dose of Hepatitis B Vaccine in Africa: Findings from Assessments in 5 Countries , 2018, Journal of immunological sciences.

[14]  F. Zoulim,et al.  Perspectives and limitations for nucleo(t)side analogs in future HBV therapies. , 2018, Current opinion in virology.

[15]  D. Smith,et al.  Occult HBV infection in HIV‐infected adults and evaluation of pooled NAT for HBV , 2018, Journal of viral hepatitis.

[16]  V. Wong,et al.  Eliminating hepatitis B virus as a global health threat. , 2016, The Lancet. Infectious diseases.

[17]  O. Opare-Sem,et al.  Screening and diagnosis of HBV in low-income and middle-income countries , 2016, Nature Reviews Gastroenterology &Hepatology.

[18]  Chien-Jen Chen,et al.  Long-term Effects of Hepatitis B Immunization of Infants in Preventing Liver Cancer. , 2016, Gastroenterology.

[19]  J. Alexander,et al.  Hepatitis B control among children in the Eastern Mediterranean Region of the World Health Organization. , 2016, Vaccine.

[20]  Y. Poovorawan,et al.  The Success of a Universal Hepatitis B Immunization Program as Part of Thailand’s EPI after 22 Years’ Implementation , 2016, PloS one.

[21]  M. Manglani,et al.  A comparative clinical study to assess safety and reactogenicity of a DTwP-HepB+Hib vaccine , 2015, Human vaccines & immunotherapeutics.

[22]  Xiaomao Li,et al.  Mother‐to‐child transmission of HBV: review of current clinical management and prevention strategies , 2014, Reviews in medical virology.

[23]  S. Rahman,et al.  Therapeutic potential of a combined hepatitis B virus surface and core antigen vaccine in patients with chronic hepatitis B , 2013, Hepatology International.

[24]  K. Narayanswamy Hepatitis B and pregnancy: challenges in India. , 2011, Journal of the Indian Medical Association.

[25]  J. Dienstag Benefits and risks of nucleoside analog therapy for hepatitis B , 2009, Hepatology.

[26]  S. Chakrabarti,et al.  Frequency and significance of hepatitis B virus surface gene variant circulating among 'antiHBc only' individuals in Eastern India. , 2007, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[27]  A. Sutanto,et al.  Implementing the birth dose of hepatitis B vaccine in rural Indonesia. , 2007, Vaccine.

[28]  T. Poynard,et al.  Coexistence of Hepatitis B Surface Antigen (HBs Ag) and Anti-HBs Antibodies in Chronic Hepatitis B Virus Carriers: Influence of “a” Determinant Variants , 2006, Journal of Virology.

[29]  Y. Hiasa,et al.  In vivo immunization by vaccine therapy following virus suppression by lamivudine: a novel approach for treating patients with chronic hepatitis B. , 2005, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[30]  A. Theamboonlers,et al.  Variants within the "a" determinant of HBs gene in children and adolescents with and without hepatitis B vaccination as part of Thailand's Expanded Program on Immunization (EPI). , 2001, The Tohoku journal of experimental medicine.

[31]  A. Zuckerman,et al.  HEPATITIS B VARIANT IN EUROPE , 1988, The Lancet.